ImmuPharma plc (FRA:25I)

Germany flag Germany · Delayed Price · Currency is EUR
0.0600
-0.0010 (-1.64%)
Last updated: Jan 28, 2026, 8:15 AM CET
-0.00%
Market Cap36.92M +138.0%
Revenue (ttm)n/a
Net Income-4.59M
EPS-0.01
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume8,076
Open0.0600
Previous Close0.0610
Day's Range0.0600 - 0.0600
52-Week Range0.0005 - 0.2180
Betan/a
RSI47.04
Earnings DateMay 18, 2026

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired aut... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 25I
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements